Skip to content

US · CSBR · BIOTECHNOLOGY

Champions Oncology, Inc. (CSBR) intrinsic value and stock valuation

$4.34as of 2026-11-21 · Mkt cap 72.11M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Champions Oncology, Inc. DCF and intrinsic value

InvestorsCraft values CSBR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CSBR’s statements →

Champions Oncology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Hackensack, NJ 07601 championsoncology.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$59.4M+7.7% 5y CAGRd
20122026
Net income
-$-1.18M
20122026
Free cash flow
-$-5.04M
20122026
Total equity
$4.07M-11.3% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$59.4M$56.9M$50.2M$53.9M$49.1M
Operating income-$-1.14M$4.85M-$-6.92M-$-4.45M$610K
Net income-$-1.18M$4.7M-$-7.28M-$-5.33M$550K
EPSd-$-85.32K$329.4K-$-537.27K-$-393.65K$38.8K
Operating cash flow-$-4.47M$7.39M-$-6.14M$3.96M$6.5M
Capital expenditure-$-560K-$-390K-$-840K-$-2.87M-$-2.38M
Free cash flow-$-5.04M$7M-$-6.97M$1.08M$4.11M
Total assets$27M$32.3M$26.1M$34.3M$35.4M
Total debt$4.59M$6.11M$7.43M$8.6M$9.47M
Net debt-$-280K-$-3.68M$4.81M-$-1.52M$460K
Total equity$4.07M$3.77M-$-1.9M$4.64M$9.1M
Cash and short-term investments$4.87M$9.79M$2.62M$10.1M$9.01M
Income statement
20262025202420232022
Revenue$59.4M$56.9M$50.2M$53.9M$49.1M
Cost of revenue$30.9M$28.4M$29.4M$29.5M$23.6M
Gross profit$28.5M$28.6M$20.8M$24.3M$25.5M
Research and development expenses$9.08M$6.83M$9.54M$11.5M$9.37M
Selling, general and administrative expenses$20.5M$16.9M$18.1M$17.2M$15.5M
Other expenses$110K$0.00$0.00$0.00$0.00
Operating expenses$29.7M$23.7M$27.7M$28.8M$24.9M
Cost and expenses$60.6M$52.1M$57.1M$58.3M$48.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.38M$1.64M$1.87M$2.25M$1.63M
Ebitda$450K$6.27M-$-5.44M-$-3.02M$2.21M
Operating income-$-1.14M$4.85M-$-6.92M-$-4.45M$610K
Total other income/expenses, net$210K-$-220K-$-390K-$-820K-$-20K
Income before tax-$-930K$4.63M-$-7.31M-$-5.27M$580K
Income tax expense$250K-$-70K-$-30K$70K$40K
Net income-$-1.18M$4.7M-$-7.28M-$-5.33M$550K
Weighted average shares outstanding$13.8M$13.7M$13.6M$13.5M$13.2M
Weighted average diluted shares outstanding$13.8M$14.3M$13.6M$13.5M$14.2M
Balance sheet
20262025202420232022
Cash and short-term investments$4.87M$9.79M$2.62M$10.1M$9.01M
Net receivables$13.2M$11.2M$9.53M$8.01M$9.51M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$19.2M$22.4M$13.6M$19.5M$19.7M
Property, plant and equipment, net$7.22M$9.46M$12M$14.5M$15.4M
Goodwill and intangible assets$340K$340K$340K$340K$340K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$7.77M$9.97M$12.5M$14.9M$15.7M
Total assets$27M$32.3M$26.1M$34.3M$35.4M
Accounts payable$6.9M$4.25M$5.8M$5.33M$2.87M
Short-term debt$1.6M$1.47M$1.34M$1.21M$1.05M
Deferred revenue$8.83M$15.4M$12.1M$12.8M$11.1M
Total current liabilities$19.9M$23.9M$21.5M$21.7M$17.5M
Long-term debt$2.99M$4.63M$6.09M$7.39M$8.41M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3M$4.72M$6.49M$7.94M$8.8M
Capital lease obligations$2.99M$6.11M$7.43M$8.6M$9.47M
Total liabilities$22.9M$28.6M$28M$29.7M$26.3M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-81.07M-$-79.89M-$-84.59M-$-77.32M-$-71.98M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$4.07M$3.77M-$-1.9M$4.64M$9.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$4.59M$6.11M$7.43M$8.6M$9.47M
Net debt-$-280K-$-3.68M$4.81M-$-1.52M$460K
Cash flow statement
20262025202420232022
Net income-$-1.18M$4.7M-$-7.28M-$-5.33M$550K
Depreciation and amortization$1.38M$1.64M$1.87M$2.25M$1.63M
Stock-based compensation$1.24M$650K$1.12M$860K$910K
Change in working capital-$-7.37M-$-620K-$-3.82M$4.24M$2.34M
Accounts receivable-$-2M-$-1.44M-$-1.99M$1.31M-$-2.82M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.56M-$-1.75M$470K$2.46M$970K
Net cash provided by operating activities-$-4.47M$7.39M-$-6.14M$3.96M$6.5M
Investments in property, plant and equipment-$-560K-$-390K-$-840K-$-2.87M-$-2.38M
Acquisitions, net$20K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-540K-$-390K-$-840K-$-2.87M-$-2.38M
Common stock issued$230K$320K$250K$90K$210K
Common stock repurchased$0.00$0.00-$-630K-$-70K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$100K$170K-$-530K$10K$210K
Net change in cash-$-4.91M$7.17M-$-7.5M$1.11M$4.32M
Cash at end of period$4.87M$9.79M$2.62M$10.1M$9.01M
Operating cash flow-$-4.47M$7.39M-$-6.14M$3.96M$6.5M
Capital expenditure-$-560K-$-390K-$-840K-$-2.87M-$-2.38M
Free cash flow-$-5.04M$7M-$-6.97M$1.08M$4.11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Champions Oncology, Inc.

        Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.

        CEO
        Robert Brainin
        Employees
        213
        Beta
        0.38

        Explore

        Frequently asked questions

        What is the intrinsic value of Champions Oncology, Inc. (CSBR)?

        InvestorsCraft does not currently publish an intrinsic value for CSBR. How the IC value is calculated.

        Is CSBR undervalued?

        InvestorsCraft does not publish an undervaluation signal for CSBR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.